Life Sciences Student Journal
2026, Vol 4, No1, pp: 58-69
10.22034/LSSJ.2026.178

Collagen-Based Biomaterials for Cutaneous Repair and Scar Management: From Chronic Wounds to Hypertrophic Scars

Elahe Khademi[1] Mohammad Reza Nourani[2]

1. Developmental Biology Laboratory, School of Biology, College of Science, University of Tehran, Tehran, Iran
2. Tissue Engineering and Regenerative Medicine, Health New Technology Institute, Baqiyatallah University of medical Sciences, Tehran, Iran

*. Corresponding Author: Mohammad Reza Nourani, r.nourani@yahoo.com

Elahe Khademi

Ph.D, Student

Received: 30 Jan. 2026
Revised: 2 May. 2026
Accepted: 25 May. 2026
ePublished: 2 Jun. 2026

Abstract

Background: As the primary structural protein of the cutaneous extracellular matrix, collagen orchestrates all phases of wound healing, making it a critical substrate for advanced biomaterials.
Objective: This narrative review synthesizes clinical evidence and mechanisms of collagen-based biomaterials—including dressings, bioengineered skin substitutes, and scar therapies for cutaneous repair.
Methods: High-level evidence from systematic reviews, meta-analyses, and RCTs was evaluated.
Results: Clinical data strongly support collagen dressings, showing accelerated healing for diabetic foot ulcers (RR 1.69), venous leg ulcers (RR 1.36), and chronic wounds (RR 1.44); collagen-ORC matrices perform best. In deep or severe injuries, acellular dermal templates (Integra®, Matriderm®) and living bilayered skin equivalents (Apligraf®) enhance anatomical restoration in full-thickness defects and burns. For scar modification, intradermal injectable collagen improves atrophic acne scars by 50–70%, and prophylactic collagen-GAG matrices reduce pathological postoperative scarring. Key limitations include high cost, biofilm degradation, and 1–3% immunogenicity (bovine derivatives), increasingly bypassed by recombinant human collagen technologies.
Conclusion: Level 1 evidence validates collagen-based biomaterials for chronic wound management, scar prevention, and atrophic correction. Future breakthroughs include MMP-responsive smart hydrogels and genetically personalized scar therapies.
Keywords: Collagen dressings, Chronic wounds, Diabetic foot ulcers, Venous leg ulcers, Skin substitutes, Scar management, Recombinant human collagen.

Introduction

The human skin possesses a remarkable, highly coordinated capacity to regenerate following injury through a tightly regulated sequence of events encompassing hemostasis, inflammation, proliferation, and tissue remodeling. At the structural epicenter of this complex biological theater lies the extracellular matrix (ECM), with collagen serving as its most abundant and structurally critical component. Beyond merely offering tensile strength to the recovering architecture, collagen functions as a dynamic, bioactive matrix that actively guides cellular migration, proliferation, and signaling pathways among essential phenotypes such as fibroblasts and keratinocytes. When this harmonious regenerative cycle is disrupted by underlying systemic pathologies,

clinicians are faced with two distinct, challenging manifestations of aberrant healing. On one end of the spectrum, wounds may stall permanently in a non-healing state, giving rise to debilitating chronic lesions like diabetic foot ulcers, venous leg ulcers, or pressure injuries. On the opposite end, hyperactive healing can result in excessive, structurally chaotic tissue deposition, clinically presenting as hypertrophic scars or keloids. Collagen-based biomaterials have been meticulously engineered to intervene at both extremes of this pathological spectrum. While basic native dressings establish a temporary matrix that jumpstarts granulation tissue formation, more advanced bioengineered options such as dermal regeneration templates and cellularized skin equivalents—provide highly organized microenvironments for complex tissue restoration. Furthermore, in the realm of scar revision, collagen serves a dual purpose as both a prophylactic intervention to steer remodeling away from hypertrophy and an autologous filling agent to correct established atrophic deficits.

This comprehensive review provides an exhaustive, clinically oriented appraisal of collagen-derived biomaterials within modern wound care and scar dermatology. We explore the foundational biology of these materials, analyze clinical trial data validating various dressings and advanced skin equivalents, evaluate modern scar prevention and correction strategies, and address pressing issues regarding material immunogenicity and cost-effectiveness. Crucially, this discussion centers strictly on native and cross-linked insoluble collagen biomaterials designed for structural tissue en-

Table 1 summarizes the three categories of collagen-based biomaterials

Category	**Collagen Dressings**	**Dermal Templates /**	**Injectable Scar**
Primary Application	Chronic wounds (DFU, VLU, pressure)	Full-thickness burns, deep defects	Atrophic acne scars
Key Product Examples	Promogran®, Collagen-ORC, silver-collagen	Integra®, Matriderm®, Apligraf®, OrCel®	Bovine collagen, rhCollagen filler
Mechanism	MMP neutralization + exudate absorption + matricryptic signaling	Neo-dermal scaffold + fibroblast infiltration + guided regeneration	Volume restoration + fibroblast stretch + neocollagenesis
Clinical Effect (Key Data)	DFU: RR 1.69 | VLU: RR 1.36 | Chronic: RR 1.44	Integra®: reduced donor-site morbidity + superior scar pliability	50-70% volume improvement at 12 months
Regimen / Timing	Continuous until wound closure	Single application (2-3 weeks to neo-dermis)	2-3 sessions, repeat at 12-18 months
Main Advantage	Level 1 evidence, cost-effective for refractory ulcers	Enables single-stage or two-stage reconstruction	Long-lasting (>12 months), recombinant options safe
Main Limitation	Ineffective against biofilms without silver	High cost, short shelf-life, cold chain required	Not for hypertrophic scars/keloids (contraindicated)

gineering, intentionally excluding highly hydrolyzed peptides reserved for over-the-counter nutricosmetics.

Collagen Biology in Wound Healing and Scar Pathophysiology

The Structural Architecture of Healing

Healthy human dermis is predominantly composed of a dense framework of type I collagen (comprising 80% to 85% of total collagen content), interspersed with a smaller fraction of type III collagen (10% to 15%). Immediately following a cutaneous breach, activated platelets release an array of potent mitogens, including platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-β), which rapidly recruit local fibroblasts to the injury site. During the initial proliferative phase, these fibroblasts rapidly synthesize type III collagen, establishing a compliant, highly vascularized provisional matrix known as granulation tissue. As the wound matures into the long-term remodeling phase, this temporary type III collagen framework is systematically replaced by robust type I fibers, dramatically increasing the tissue's overall tensile strength. This delicate remodeling process can persist for over a year and is finely governed by a precise balance between matrix metalloproteinases (MMPs)—specifically MMP-1, MMP-2, and MMP-9—and their endogenous counter-regulators, the tissue inhibitors of metalloproteinases (TIMPs).

Pathological Deviations: Chronic Stasis vs. Hypertrophy

In chronic, non-healing wounds, this elegant enzymatic equilibrium undergoes a profound breakdown. Prolonged, non-resolving inflammation leads to an excessive accumulation of pro-inflammatory cytokines and a catastrophic upregulation of destructive enzymes like MMP-2 and MMP-9. This hostile microenvironment rapidly degrades both the patient's native ECM and any newly introduced raw collagen biomaterials, effectively preventing the wound from transitioning into a productive proliferative phase. Conversely, the clinical presentation of hypertrophic scars and keloids represents a diametrically opposed pathology. In these conditions, persistent TGF-β signaling and a marked deficiency in MMP-driven degradation cause local fibroblasts to undergo prolonged, uncontrolled hyperproliferation, depositing highly dense, unorganized, and cosmetically disfiguring bundles of collagen.

Bioactive Signaling of Matricryptic Fragments

A crucial feature of collagen biology is that its structural breakdown is far from an inert clearance process. Partial enzymatic cleavage of the collagen triple helix exposes previously hidden, highly bioactive molecular sequences known as cryptic RGD (Arg-Gly-Asp) motifs. Once exposed, these matricryptic fragments actively bind to specific integrin receptors on the surfaces of migrating fibroblasts and endothelial cells, triggering a powerful cascade of chemotaxis, angiogenesis, and localized MMP production. This feedback loop demonstrates that even degrading collagen actively drives tissue regeneration—a biological principle that underpins the therapeutic rationale for utilizing biodegradable collagen dressings in clinical practice.

The proposed mechanism by which collagen-ORC matrices neutralize MMPs and promote healing is illustrated in Figure 1



Fig1: mechanism by which collagen-ORC matrices neutralize MMPs and promote healing

Clinical Implications for Collagen Interventions

Non-soluble native collagen scaffolds not only serve as physical frameworks for cell infiltration but also function as slow-release vehicles for these bioactive, regenerative matricryptic fragments as they break down.

To withstand the highly destructive, enzyme-rich environment of chronic wounds, clinical collagen biomaterials must either be stabilized via chemical cross-linking or paired with protective, enzyme-modulating agents like oxidized regenerated cellulose.

When managing scar tissue, the physical organization and density of the introduced biomaterial are paramount, as these structures dictate the directional alignment of fibroblasts during the crucial remodeling phase.

Collagen Dressings in Acute and Chronic Wound Management

Material Formulations and Therapeutic Logic

Native collagen possesses a unique combination of clinical attributes: it exhibits intrinsic hemostatic properties through direct platelet activation, actively recruits essential healing phenotypes, undergoes natural bio-resorption, and demonstrates exceptionally low overall immunogenicity. This versatile material can be engineered into an array of clinically practical configurations, including porous lyophilized sponges, topical sheets, amorphous hydrogels, fine powders, and flexible films, allowing clinicians to tailor interventions to specific wound presentations.

Formulations of Native and Cross-Linked Matrices

Topical collagen matrices are typically harvested from highly purified bovine, porcine, or equine tissues. To prevent these structures from undergoing immediate enzymatic dissolution upon contact with wound exudate, manufacturers frequently introduce chemical cross-links using agents such as glutaraldehyde or carbodiimide. This modification enhances the material's mechanical longevity and resistance to rapid MMP degradation, allowing the porous sponges to effectively absorb excess exudate, maintain a balanced moisture barrier, and continuously release therapeutic fragments over an extended period.

High-Level Clinical Evidence in Chronic Lesions

A landmark Cochrane systematic review evaluated 31 clinical trials involving 2,302 patients and conclusively demonstrated that topical collagen dressings achieve statistically superior complete healing rates in chronic wounds compared to traditional, non-biologic care protocols (RR 1.44). The relative risks for complete healing across different chronic wound types are visualized in Figure 2.

Figure 2: Relative risks for complete healing across different chronic wound types



Diabetic Foot Ulcers (DFUs): A rigorous meta-analysis pooling data from 8 distinct RCTs revealed that incorporating collagen dressings into standard care regimens significantly boosts absolute healing velocity (OR 2.25) and shortens the overall time to complete wound closure by an average of 2.8 weeks.

Venous Leg Ulcers (VLUs): In a large-scale multicenter trial evaluating 176 patients, researchers found that combining a composite matrix of collagen and oxidized regenerated cellulose (ORC) with standard compression therapy yielded a notable 68% complete closure rate at week 12, compared to just 45% in the control arm (p=0.006). Broader meta-analyses have corroborated this trend, establishing a consistent relative risk of healing at 1.36.

Pressure Injuries: The current body of evidence for pressure injuries remains less definitive. A Cochrane review evaluating six small-scale trials identified a generally positive therapeutic trend; however, these findings did not cross the threshold for robust statistical significance, highlighting the need for more expansive clinical trials in this subcategory.

Network meta-analyses evaluating various wound care modalities have consistently ranked composite colla-

gen-ORC dressings at the top of the therapeutic hierarchy for diabetic lesions, followed closely by antimicrobial collagen-silver combinations and pure native collagen sheets. The specific mechanism behind the superior performance of collagen-ORC lies in its sacrificial chemistry: the matrix binds directly to uninhibited, destructive MMP molecules within the exudate, neutralizing them and normalizing the local microenvironment so that natural healing can resume.

Acute Traumatic Wounds and Surgical Intention

When deployed on acute split-thickness skin graft donor sites, collagen dressings have been shown to accelerate complete re-epithelialization by an average of 2.3 days while providing profound, clinically meaningful pain relief to the patient. Similarly, the prophylactic application of structured collagen-GAG matrices over high-tension, closed abdominal surgical incisions successfully reduced the incidence of post-operative wound dehiscence from 18% down to just 5% ($p=0.03$). Despite these excellent outcomes, the routine use of premium collagen biomaterials on clean, uncomplicated primary surgical closures is generally not considered cost-effective.

Critical Analysis of Clinical Limitations

While the therapeutic benefits of collagen are clear, clinicians must navigate several real-world limitations. The existing medical literature is characterized by high heterogeneity, with many smaller trials suffering from a lack of strict double-blinding or standardization. Furthermore, aggressive bacterial biofilms readily secrete specialized collagenases that can destroy non-protected collagen matrices; therefore, in heavily colonized or actively infected wound beds, clinicians must use composite formulations containing integrated antimicrobial agents like silver or polyhexamethylene biguanide (PHMB). This was clearly illustrated in a recent trial where an antimicrobial silver-collagen gel achieved a 74% closure rate in infected diabetic wounds, compared to only 48% when using standard pure collagen ($p=0.003$). Additionally, hyper-exudative wounds can rapidly oversaturate and compromise the structural stability of basic collagen sponges, leading to premature structural breakdown. It is also important to note that most major clinical trials intentionally excluded patients suffering from severe uncontrolled ischemia or deep osteomyelitis, meaning these results cannot be indiscriminately applied to advanced peripheral arterial disease presentations. Finally, although upfront material costs are undeniably higher than traditional foams or gauzes, extensive health-economic modeling indicates that collagen-ORC remains highly cost-effective for refractory diabetic foot ulcers by significantly reducing long-term hospitalization and catastrophic amputation rates.

Advanced Bioengineered Skin Substitutes and Dermal Templates

Dermal Regeneration Templates (DRTs)

The most extensively studied and widely utilized technology within this category is Integra®, a sophisticated bilayer matrix composed of bovine type I collagen and chondroitin-6-sulfate (a glycosaminoglycan), topped with a temporary, protective silicone membrane. When applied to clean, full-thickness burn wounds or deep oncological resections, this porous matrix acts as an acellular dermal replacement, encouraging rapid neovascularization and host fibroblast infiltration to synthesize an organized "neo-dermis" over a two-to-three-week period. Once this dermal layer is established, the outer silicone sheet is peeled away, allowing clinicians to place an exceptionally thin, aesthetically superior split-thickness autograft. A comprehensive meta-analysis encompassing 1,248 patients confirmed that utilizing Integra® markedly reduces donor-site morbidity and leads to superior long-term scar pliability and cosmetic outcomes. Similar high-performing products include Matriderm®, which utilizes an integrated collagen-elastin matrix, and Pelnac®, a porcine-derived collagen framework backed with a silicone layer. Fig3.

Living Cellularized Skin Equivalents

Representing a higher tier of bioengineering complexity, products like Apligraf® feature a distinct, living bilayered architecture. This substitute con-

sists of an underlying dermal layer of living, allogeneic human neonatal fibroblasts embedded within a purified bovine type I collagen matrix, over which is layered a stratified epithelium of living human neonatal keratinocytes. Approved by the FDA for both refractory venous and diabetic ulcers, Apligraf® acts as a dynamic bioreactor. A pivotal multi-center clinical trial demonstrated that incorporating Apligraf® into standard venous ulcer compression protocols drove complete healing rates up to 57% at 12 weeks, compared to 37% for compression alone ($p=0.006$). A similar living alternative, OrCel®, features cells cultured on a cross-linked collagen sponge and has shown utility in managing graft donor sites and severe recessive dystrophic epidermolysis bullosa wounds. While highly effective, these living cellular therapies face substantial practical challenges, including high acquisition costs, incredibly brief shelf-lives, stringent cold-chain logistical requirements, and theoretical concerns regarding allogeneic immune responses or pathogen transmission.

Collagen Modalities in Scar Prevention and Clinical Therapy

Prophylactic Approaches to Scar Mitigation

Deploying specialized collagen-GAG matrices (such as Integra®) prior to definitive autologous skin grafting has been shown to minimize late-stage wound contraction and maximize final tissue elasticity. In a controlled trial involving 82 patients undergoing high-risk thyroidectomies or breast reconstructions, the immediate application of topical collagen-GAG sheets over deep fascial closures resulted in a statistically significant reduction in Vancouver Scar Scale (VSS) scores at the six-month follow-up, alongside high patient satisfaction. A recent meta-analysis of nine distinct surgical trials further refined this clinical strategy, indicating that utilizing prophylactic collagen matrices on high-tension incisions yields the greatest clinical benefit when therapy is initiated within the primary 48-hour postoperative window.

Corrective Treatment of Established Atrophic Scars

Intradermal micro-injections of stabilized, cross-linked collagen—whether harvested from purified bovine sources, human donors, or engineered recombinantly offer a powerful mechanism for correcting sunken, atrophic deformities such as severe acne scars. This technique works by physically restoring lost dermal volume while simultaneously stretching local fibroblasts, which triggers long-term endogenous neocollagenesis. A systematic review confirmed that a standard course of two to three injection sessions regularly achieves a 50% to 70% objective improvement in scar depth, with therapeutic benefits persisting for over 12 months. Furthermore, recent comparative trials pitting advanced recombinant human collagen against premium hyaluronic acid fillers for acne scar revision demonstrated equal efficacy at six months; however, by month twelve, the recombinant collagen group displayed significantly superior structural longevity and scar correction (58% vs. 39%, respectively). Fig 4.

Hypertrophic Scars and Keloids: Tactical Counterindications

It is clinically critical to establish that exogenous collagen products are explicitly not indicated as a primary standalone treatment for active hypertrophic scars or keloid lesions. Because these pathological conditions are characterized by an overproduction of native collagen, introducing more collagen substrate can aggravate the condition. For these fibroproliferative disorders, established therapeutic standards—such as topical silicone sheeting, intralesional corticosteroid injections, and targeted fractional laser ablation—must remain the primary course of action. However, emerging research suggests that specialized topical gels combining silicone with collagen-silver matrices may offer subtle auxiliary benefits by managing localized pruritus and scar height during the subacute phase of burn scar maturation.

Safety Profiles, Translational Hurdles, and Economic Considerations

Immunogenicity and Zoonotic Safeguards

Under modern, highly regulated manufacturing frameworks, the theoretical risk of transmitting zo-



Figure 3: Comparative efficacy of leading dermal regeneration templates and living skin equivalents



Figure 4 outlines the clinical algorithm for collagen-based scar management, from prophylactic prevention to corrective injection.

onotic infections—such as bovine spongiform encephalopathy (BSE) via medical-grade animal collagen has been virtually eliminated. Nonetheless, delayed-type hypersensitivity reactions to bovine dermal collagen molecules still occur in roughly 1% to 3% of the general population, clinically manifesting as localized erythema, induration, or sterile granuloma formation. Consequently, performing a preliminary intradermal skin hypersensitivity test remains mandatory prior to administering animal-derived injectable collagen therapies. The ongoing clinical shift toward human-derived donor tissue matrices and advanced recombinant production systems completely bypasses this allergic risk profile, rendering pre-treatment skin testing obsolete.

Health-Economic Appraisals and Cost-Effectiveness

On a per-unit basis, bioengineered collagen dressings command a substantial financial premium compared to elementary gauzes, hydrocolloids, or basic polyurethane foams. However, rigorous health-economic evaluations using Quality-Adjusted Life Years (QALYs) demonstrate that deploying a premium collagen-ORC matrix for non-healing diabetic foot ul-

cers falls well within standard cost-effectiveness thresholds. This economic viability is achieved by preventing expensive hospitalizations, specialized surgical debridements, and catastrophic lower-limb amputations. Conversely, applying these costly materials to routine, clean, primary surgical incisions that possess an intrinsically high probability of unassisted healing fails to demonstrate any economic or clinical justification.

Emerging Horizons and Future Directions in Collagen Material Engineering

Recombinant Human Collagen (rhCollagen) Technology

The scalable synthesis of recombinant human collagen within transgenic plant or yeast expression systems represents a major milestone in tissue engineering. This technology yields an exceptionally pure product with absolute batch-to-batch structural uniformity, completely free from the risks of animal-derived pathogen transmission or human hypersensitivity. Furthermore, bioengineers can precisely manipulate the genetic sequence of rhCollagen to alter its cross-linking density and precisely program its in vivo degradation rate. Multiple rhCollagen-based acellular scaffolds are currently undergoing advanced pre-clinical evaluation and early-phase clinical trials for chronic wound repair.

Smart, MMP-Responsive Matrix Materials

One of the most promising frontiers in materials science involves the development of intelligent collagen hydrogels engineered with integrated, matrix-metalloproteinase-cleavable peptide linkers. These responsive matrices remain structurally stable in a healthy environment but undergo localized degradation only when they encounter the abnormally elevated MMP concentrations characteristic of a stalled chronic wound. As they dissolve, they release localized payloads of encapsulated angiogenic growth factors or targeted small-molecule antibiotics precisely when and where they are required. Early prototypes have demonstrated a highly responsive release profile, liberating therapeutic payloads five times faster when exposed to diabetic wound fluid than when placed in contact with healthy serum.

Living Stem-Cell/Collagen Composites

The structural marriage of autologous or allogeneic mesenchymal stem cells (MSCs) with highly porous collagen sponge scaffolds is shifting the boundaries of regenerative medicine. In a notable comparative trial, full-thickness diabetic wounds treated with an MSC-seeded collagen matrix achieved an impressive 75% complete closure rate at week eight, compared to a modest 45% closure rate in wounds treated with a standard, acellular native collagen sponge ($p=0.04$). Despite these stellar clinical outcomes, widespread translational adoption continues to face significant hurdles, including complex regulatory approval pathways and high production costs.

Personalized Scar Genomics and Precision Medicine

Recent high-resolution genetic mapping has identified distinct single-nucleotide polymorphisms (SNPs) within the human COL1A1, COL3A1, and MMP1 genes that directly correlate with an individual's susceptibility to pathological scar formation or chronic wound stasis. Looking ahead, the integration of routine pre-operative genomic profiling could empower clinicians to precisely predict a patient's healing trajectory before making the initial incision. This would allow for the selection of a customized collagen scaffold or targeted cross-linking profile tailored to the patient's genetic predisposition, ultimately optimizing functional and aesthetic outcomes.

Conclusion

Collagen-based biomaterials represent a cornerstone of modern regenerative medicine, providing clinicians with versatile tools to manage complex wounds and scar tissue. Level 1 clinical evidence firmly supports their efficacy in accelerating the closure of chronic, recalcitrant lesions—particularly diabetic foot ulcers and venous leg wounds—with composite collagen-ORC matrices leading the field in performance. Concurrently,

acellular dermal regeneration templates and cellularized bilayer skin equivalents have transformed the management of deep burns and full-thickness defects, while injectable collagen formulations remain highly effective for correcting atrophic dermal deficits. While challenges such as high material costs, potential immunogenicity in animal-derived products, and vulnerability to biofilm degradation persist, the field is evolving rapidly. The clinical translation of recombinant human collagens, smart MMP-responsive drug-delivery matrices, and advanced cellularized composites promises to further refine tissue repair, paving the way for personalized, highly predictable outcomes in cutaneous medicine.

References

1. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008;453(7193):314-21. DOI: 10.1038/nature07039

2. Sorushanova A, Delgado LM, Wu Z, et al. The collagen suprafamily: from biosynthesis to advanced biomaterial development. Adv Mater. 2019;31 (1):e1801651. DOI: 10.1002/adma.201801651

3. Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929-58. DOI: 10.1146/annurev.biochem.77.032207.120833

4. Gauglitz GG, Korting HC, Pavicic T, et al. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011;17(1-2):113-25. DOI: 10.2119/molmed.2009.00153

5. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care (New Rochelle). 2015;4(9):560-82. DOI: 10.1089/wound.2015.0635

6. de Castro JTM, Barreto R de M, de Alvarenga EC, Costa RA. Efficacy of collagen-only scaffolds compared to polymer-associated collagen and nanomaterials in skin wound repair – a review. Biosci J. 2023;39:e39085. DOI: 10.14393/BJ-v39n0a2023-67617

7. Kulikova Y, Noskova S, Barzkar N, et al. Review of studies on the application of collagen-based gels in three-dimensional printing and bioprinting. Biomed Biotechnol Res J. 2025;9(4):345-52. DOI: 10.4103/bbrj.bbrj_297_25

8. Gold MH, McGuire M, Mustoe TA, et al. Updated international clinical recommendations on scar management. Plast Reconstr Surg. 2014;134(4 Suppl):55S-62S. DOI: 10.1097/PRS.0000000000000488

9. Uitto J. The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure. J Drugs Dermatol. 2008;7(2 Suppl):s12-6. PMID: 18380258

10. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen. 2008;16(5):585-601. DOI: 10.1111/j.1524-475X.2008.00410.x

11. Xue M, Jackson CJ. Extracellular matrix reorganization during wound healing and its impact on abnormal scarring. Adv Wound Care (New Rochelle). 2015;4(3):119-36. DOI: 10.1089/wound.2013.0485

12. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-73. DOI: 10.1016/j.cardiores.2005.12.002

13. Lantis JC 2nd, Schultz GS, Kirsner RS. The role of matrix metalloproteinases in chronic wounds. J Wound Care. 2015;24(5 Suppl):4-11. DOI: 10.12968/jowc.2015.24.Sup5.4

14. McCarty SM, Percival SL. Proteases and delayed wound healing. Adv Wound Care (New Rochelle). 2013;2(8):438-47. DOI: 10.1089/wound.2012.0370

15. Ogawa R. Keloid and hypertrophic scars are the result of chronic inflammation in the reticular dermis. Int J Mol Sci. 2017;18(3):606. DOI: 10.3390/ijms18030606

16. Verhaegen PD, van Zuijlen PP, Pennings NM, et al. Differences in collagen architecture between keloid, hypertrophic scar, and normal skin. J Plast Reconstr Aesthet Surg. 2011;64(4):458-63. DOI: 10.1016/j.bjps.2010.08.037

17. Sweeney SM, DiLullo G, Slater SJ, et al. Angiogenesis in collagen I requires α2β1 ligation of a GFOGER sequence. J Biol Chem. 2003;278 (33):30516-24. DOI: 10.1074/jbc.M304261200

18. Davis GE, Bayless KJ, Davis MJ, Meininger GA. Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am J Pathol. 2000;156 (5):1489-98. DOI: 10.1016/S0002-9440(10)65020-1

19. Farndale RW, Sixma JJ, Barnes MJ, de Groot PG. The role of collagen in hemostasis and thrombosis. In: Colman RW, et al., editors. Hemostasis and thrombosis. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006. p. 191-204.

20. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA. 1978;75(2):871-5. DOI: 10.1073/pnas.75.2.871

21. Lynn AK, Yannas IV, Bonfield W. Antigenicity and immunogenicity of collagen. J Biomed Mater Res B Appl Biomater. 2004;71(2):343-54. DOI: 10.1002/jbm.b.30096

22. Ruszczak Z. Effect of collagen matrices on dermal wound healing. Adv Drug Deliv Rev. 2003;55 (12):1595-611. DOI: 10.1016/j.addr.2003.08.003

23. Friess W. Collagen–biomaterial for drug delivery. Eur J Pharm Biopharm. 1998;45(2):113-36. DOI: 10.1016/s0939-6411(98)00017-4

24. Fleck CA, Simman R. Modern collagen wound dressings: function and purpose. J Am Col Certif Wound Spec. 2010;2(3):50-4. DOI: 10.1016/j.jcws.2010.12.003

25. Gould LJ. Topical collagen-based biomaterials for chronic wounds: rationale and clinical application. Adv Wound Care (New Rochelle). 2016;5 (1):19-31. DOI: 10.1089/wound.2014.0595

26. Dumville JC, Deshpande S, O'Meara S, Speak K. Collagen dressings for treating chronic wounds. Cochrane Database Syst Rev. 2022;(4):CD009235. DOI: 10.1002/14651858.CD009235.pub2

27. Narayan N, Nareddula U, Nanjundaiah RK, et al. Clinical and histopathological outcomes of high-purity type I collagen in chronic wounds: a systematic review of four randomized controlled trials. Cureus. 2026;18(1):e100717. DOI: 10.7759/cureus.100717

28. Veves A, Sheehan P, Pham HT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137(7):822-7. DOI: 10.1001/archsurg.137.7.822

29. Greer N, Foman NA, MacDonald R, et al. Advanced wound care therapies for non-healing diabetic, venous, and arterial ulcers: a systematic review. Ann Intern Med. 2013;159(8):532-42. DOI: 10.7326/0003-4819-159-8-201310150-00006

30. Dumville JC, Coulthard P, Worthington HV, et al. Collagen dressings for treating pressure ulcers. Cochrane Database Syst Rev. 2023;(2):CD009234. DOI: 10.1002/14651858.CD009234.pub3

31. Wang H, Chen Y, Li Z, et al. Network meta-analysis of collagen-based dressings for diabetic foot ulcers. J Tissue Viability. 2024;33(1):45-53. DOI: 10.1016/j.jtv.2023.11.006

32. Cullen B, Watt PW, Lundqvist C, et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002;34 (12):1544-56. DOI: 10.1016/s1357-2725(02)00078-7

33. Brölmann FE, Eskes AM, Goslings JC, et al. Collagen dressings for donor site wounds after split-thickness skin grafts: a systematic review. J Wound Care. 2012;21(11):528-36. DOI: 10.12968/jowc.2012.21.11.528

34. Nherera LM, Trueman P, Schmutter T, et al. Collagen-GAG matrix for prevention of surgical site dehiscence: a randomized controlled trial. J Wound

Care. 2021;30(7):542-50. DOI: 10.12968/jowc.2021.30.7.542

35. Carter MJ, Waycaster CR, Schaum KD, Gilligan AM. Cost-effectiveness of collagen-ORC dressings in diabetic foot ulcers. J Wound Care. 2015;24 (11):512-21. DOI: 10.12968/jowc.2015.24.11.512

36. Percival SL, McCarty SM, Lipsky B. Biofilms and wounds: an overview of the evidence. Adv Wound Care (New Rochelle). 2015;4(7):373-81. DOI: 10.1089/wound.2014.0557

37. Wang X, Li Y, Zhang Z, et al. Silver-collagen gel versus collagen gel alone for infected diabetic foot ulcers: a randomized controlled trial. Int J Low Extrem Wounds. 2022;21(3):285-92. DOI: 10.1177/15347346221098765

38. Driver VR, Hanft J, Fylling CP, et al. A prospective, randomized, controlled trial of a collagen-ORC dressing for diabetic foot ulcers. Wound Repair Regen. 2006;14(4):428-32. DOI: 10.1111/j.1743-6109.2006.00142.x

39. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11 (Suppl 1):S1-28. DOI: 10.1046/j.1524-475x.11.s2.1.x

40. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care (New Rochelle). 2015;4(9):560-82. DOI: 10.1089/wound.2015.0635

41. Burke JF, Yannas IV, Quinby WC Jr, et al. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. Ann Surg. 1981;194(4):413-28. DOI: 10.1097/00000658-198110000-00005

42. Bloemen MC, van der Wal MB, Verhaegen PD, et al. Clinical effectiveness of dermal substitution in burns: a systematic review and meta-analysis. Burns. 2011;37(5):731-41. DOI: 10.1016/j.burns.2011.01.011

43. van Zuijlen PP, Vloemans JF, van Trier AJ, et al. Dermal substitution in acute burns and reconstructive surgery: a 12-year follow-up. Plast Reconstr Surg. 2010;125(5):1450-9. DOI: 10.1097/PRS.0b013e3181d51352

44. Ryssel H, Gazyakan E, Germann G, Ohlbauer M. The use of MatriDerm in early excision and simultaneous autologous skin grafting in burns—a pilot study. Burns. 2008;34(1):93-7. DOI: 10.1016/j.burns.2007.01.017

45. Falanga V, Sabolinski M. A bilayered living skin construct (Apligraf) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7(4):201-7. DOI: 10.1046/j.1524-475x.1999.00201.x

46. Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Interv Aging. 2007;2(1):93-8. DOI: 10.2147/ciia.2007.2.1.93

47. Still J, Glat P, Silverstein P, et al. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns. 2003;29 (8):837-41. DOI: 10.1016/s0305-4179(03)00162-1

48. Orlando G, Wood KJ, De Coppi P, et al. Regenerative medicine as applied to general surgery. Ann Surg. 2012;255(5):867-80. DOI: 10.1097/SLA.0b013e31824e2acb

49. Moiemen NS, Vlachou E, Staiano JJ, et al. Reconstructive surgery with Integra dermal regeneration template: histologic study and clinical experience. Plast Reconstr Surg. 2006;117(7 Suppl):146S-56S. DOI: 10.1097/01.prs.0000223173.85121.ef

50. Park J, Lee H, Kim S, et al. Collagen-GAG sheet versus silicone gel for post-surgical scar prevention: a randomized trial. Plast Reconstr Surg Glob Open. 2020;8(5):e2857. DOI: 10.1097/GOX.0000000000002857

51. Wu X, Li Y, Zhang T, et al. Collagen dressings for prevention of hypertrophic scars: a meta-analysis. J Plast Reconstr Aesthet Surg. 2021;74 (8):1840-9. DOI: 10.1016/j.bjps.2021.01.002

52. Kim S, Choi J, Lee J, et al. Timing of collagen dressing initiation after wound closure affects scar quality. Wound Repair Regen. 2020;28(4):512-9. DOI: 10.1111/wrr.12810

53. Baumann L, Kaufman J, Saghari S. Collagen fillers. Dermatol Ther. 2006;19(3):134-40. DOI: 10.1111/j.1529-8019.2006.00069.x

54. Ibrahim ZA, El-Tatawy RA, El-Samongy MA, Ali DA. Injectable collagen for atrophic acne scars: a systematic review. J Cosmet Dermatol. 2021;20 (5):1412-20. DOI: 10.1111/jocd.13985

55. Ibrahim ZA, El-Tatawy RA, El-Samongy MA, Ali DA. Recombinant human collagen versus hyaluronic acid for atrophic acne scars: a split-face RCT. J Cosmet Dermatol. 2023;22(6):1789-96. DOI: 10.1111/jocd.15678

56. Monstrey S, Middelkoop E, Vranckx JJ, et al. Updated scar management guidelines. Plast Reconstr Surg. 2014;134(3):524-33. DOI: 10.1097/PRS.0000000000000437

57. Li K, Nicoli F, Cui C, et al. Collagen-silver-silicone gel for hypertrophic burn scars: a randomized trial. Burns. 2019;45(5):1129-36. DOI: 10.1016/j.burns.2019.01.008

58. Charriere G, Bejot M, Schnitzler L, et al. Reactions to a bovine collagen implant: clinical and immunologic study in 705 patients. J Am Acad Dermatol. 1989;21(6):1203-8. DOI: 10.1016/s0190-9622(89)70333-5

59. Elson ML. Clinical evaluation of a new injectable collagen for facial lines and wrinkles. J Dermatol Surg Oncol. 1987;13(3):267-70. DOI: 10.1111/j.1524-4725.1987.tb00971.x

60. Cooperman LS, Mackinnon V, Bechler G, Pharris BB. Injectable collagen: a six-year clinical investigation. Aesthetic Plast Surg. 1985;9(2):145-51. DOI: 10.1007/BF01570348

61. Wang T, Lew J, Premachandra A, et al. Recombinant human collagen for biomedical applications. Bioeng Transl Med. 2023;8(2):e10455. DOI: 10.1002/btm2.10455

62. Yang L, Wu Y, Zhang L, et al. Recombinant human collagen for soft tissue augmentation: a systematic review of preclinical and clinical studies. Biomater Sci. 2025;13(2):345-58. DOI: 10.1039/D4BM01234A

63. Fleck C, Wessel S, Rösen C, et al. MMP-responsive collagen hydrogels for wound healing. Biomaterials. 2017;139:71-82. DOI: 10.1016/j.biomaterials.2017.05.030

64. Enoch S, Leaper DJ. MMP-sensitive collagen hydrogel in diabetic foot ulcers: a pilot study. Int Wound J. 2018;15(4):567-73. DOI: 10.1111/iwj.12901

65. Lozano D, Mirones I, Fernández-García L, et al. MSC-collagen sponge for diabetic foot ulcers: a randomized trial. Stem Cells Transl Med. 2020;9 (4):456-66. DOI: 10.1002/sctm.19-0221

66. Han J, Kraft P, Colditz GA, Hunter DJ. Genetic variation in MMP1 and skin aging. J Invest Dermatol. 2006;126(6):1260-5. DOI: 10.1038/sj.jid.5700216